Drugs Resistance in Heart Diseases
暂无分享,去创建一个
R. Ullah | A. Baig | A. Mahmood | Arshad Islam | Maryam Eqan | Saher Pervez | Rimsha Javed | Ajmal Khan | Gotam Kumar | Muhammad Abaid-Ullah | M. Rafiq
[1] J. Padovan,et al. Three Generations of β-blockers: History, Class Differences and Clinical Applicability. , 2019, Current hypertension reviews.
[2] Takashi Ito,et al. Uric acid enhances alteplase-mediated thrombolysis as an antioxidant , 2018, Scientific Reports.
[3] Ashkan Karimi,et al. Thiazide Therapy in Chronic Kidney Disease: Renal and Extra Renal Targets. , 2018, Current drug metabolism.
[4] J. Ambrose,et al. Understanding myocardial infarction , 2018, F1000Research.
[5] G. Lip,et al. Antiarrhythmic drugs-clinical use and clinical decision making: a consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society , 2018, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[6] U. Alon. The Effects of Diuretics on Mineral and Bone Metabolism. , 2018, Pediatric endocrinology reviews : PER.
[7] F. Fernández‐Avilés,et al. Impact of age and sex on survival and causes of death in adults with congenital heart disease. , 2017, International journal of cardiology.
[8] O. Ziff,et al. Digoxin: The good and the bad. , 2016, Trends in cardiovascular medicine.
[9] L. Wilkins. 2013 ACC/AHA Cholesterol Guideline and Implications for Healthy People 2020 Cardiovascular Disease Prevention Goals , 2016, Journal of the American Heart Association.
[10] A. Šukalo,et al. Treatment of Hypertension with Combination of Lisinopril/Hydrochlorothiazide , 2016, Medical archives.
[11] Nora Macleod-Glover,et al. Digoxin toxicity: Case for retiring its use in elderly patients? , 2016, Canadian family physician Medecin de famille canadien.
[12] I. Asher,et al. Angiotensin-converting enzyme inhibitor-induced angioedema. , 2015, The American journal of medicine.
[13] P. Nanasi,et al. The Janus face of adenosine: antiarrhythmic and proarrhythmic actions. , 2014, Current pharmaceutical design.
[14] R. Khatib,et al. Pharmacology of Medications Used in the Treatment of Atherosclerotic Cardiovascular Disease , 2014 .
[15] J. Hallas,et al. Classification of myocardial infarction: frequency and features of type 2 myocardial infarction. , 2013, The American journal of medicine.
[16] R. Schwinger,et al. Cardio-selective beta-blocker: pharmacological evidence and their influence on exercise capacity. , 2013, Cardiovascular therapeutics.
[17] B. Funke,et al. Dilated cardiomyopathy , 2007, Archives of Disease in Childhood.
[18] B. Dong,et al. Long-term beta blockers for stable angina: systematic review and meta-analysis , 2012, European Journal of Preventive Cardiology.
[19] P. Rao. Congenital Heart Disease - Selected Aspects , 2012 .
[20] G. Ellrodt,et al. Verapamil: A Review of its Pharmacological Properties and Therapeutic Use , 1978, Drugs.
[21] K. Vrana,et al. Elsevier's integrated review pharmacology , 2012 .
[22] Julio C. B. Ferreira,et al. Nitroglycerin use in myocardial infarction patients. , 2012, Circulation journal : official journal of the Japanese Circulation Society.
[23] J. Rush,et al. Safety Profiles of the Angiotensin-Converting Enzyme Inhibitors , 2012, Drugs.
[24] W. Cushman,et al. Thiazide and Loop Diuretics , 2011, Journal of clinical hypertension.
[25] A. Fares. Night-time exogenous melatonin administration may be a beneficial treatment for sleeping disorders in beta blocker patients , 2011, Journal of cardiovascular disease research.
[26] N. Dhalla,et al. β-adrenergic blockade attenuates cardiac dysfunction and myofibrillar remodelling in congestive heart failure , 2010, Journal of cellular and molecular medicine.
[27] T. K. Agasti,et al. Textbook of anaesthesia for postgraduates , 2011 .
[28] Jason L Salemi,et al. Mortality Resulting From Congenital Heart Disease Among Children and Adults in the United States, 1999 to 2006 , 2010, Circulation.
[29] H. Vandekerckhove,et al. Beta-blockers: focus on mechanism of action Which beta-blocker, when and why? , 2010, Acta cardiologica.
[30] N. Dhalla,et al. Mechanisms of the beneficial effects of beta-adrenoceptor antagonists in congestive heart failure. , 2010, Experimental and clinical cardiology.
[31] M. Diplomate,et al. 8. Cardiovascular System , 2009 .
[32] D. Ellison,et al. Thiazide Effects and Adverse Effects: Insights From Molecular Genetics , 2009, Hypertension.
[33] M. Weir. β-Blockers in the Treatment of Hypertension: Are There Clinically Relevant Differences? , 2009, Postgraduate medicine.
[34] Felix Yang,et al. Quinidine revisited. , 2009, The American journal of medicine.
[35] Matthew J Strickland,et al. Prevalence of congenital heart defects in metropolitan Atlanta, 1998-2005. , 2008, The Journal of pediatrics.
[36] J. Cruickshank. Initial management of cardiac arrhythmias. , 2008, Australian family physician.
[37] S. Gordon,et al. Drugs used in the management of heart disease and cardiac arrhythmias , 2008 .
[38] S. Bozkurt,et al. Cardiovascular toxicity due to metoprolol poisoning in a patient with coronary artery disease. , 2007, British journal of clinical pharmacology.
[39] G. Gamba,et al. Thiazide diuretics directly induce osteoblast differentiation and mineralized nodule formation by interacting with a sodium chloride co-transporter in bone. , 2007, Journal of the American Society of Nephrology.
[40] Jeffrey A. Feinstein,et al. Noninherited Risk Factors and Congenital Cardiovascular Defects: Current Knowledge: A Scientific Statement From the American Heart Association Council on Cardiovascular Disease in the Young , 2007, Circulation.
[41] P. Palatini,et al. Autonomic nervous system function in chronic hypotension associated with Bartter and Gitelman syndromes. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[42] G. Hankey,et al. Aspirin resistance , 2006, The Lancet.
[43] M. Ritter,et al. Thiazide-sensitive NaCl-cotransporter in the Intestine , 2005, Journal of Biological Chemistry.
[44] K. Swedberg,et al. [Expert Consensus document on beta-adrenergic receptor blockers]. , 2004, Revista espanola de cardiologia.
[45] A. Hughes,et al. How do thiazide and thiazide-like diuretics lower blood pressure? , 2004, Journal of the renin-angiotensin-aldosterone system : JRAAS.
[46] C. January,et al. Biology of cardiac arrhythmias: ion channel protein trafficking. , 2004, Circulation research.
[47] G. A. West,et al. Sinus slowing and pacemaker shift caused by adenosine in rabbit SA node , 2004, Pflügers Archiv.
[48] R. Macallister,et al. Vascular natriuretic peptide receptor‐linked particulate guanylate cyclases are modulated by nitric oxide–cyclic GMP signalling , 2003, British journal of pharmacology.
[49] D. Grobbee,et al. Blood pressure response to changes in sodium and potassium intake: a metaregression analysis of randomised trials , 2003, Journal of Human Hypertension.
[50] J. Vane,et al. The mechanism of action of aspirin. , 2003, Thrombosis research.
[51] C. Billington,et al. Signaling and regulation of G protein-coupled receptors in airway smooth muscle , 2003, Respiratory research.
[52] R. Collins,et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies , 2002, The Lancet.
[53] J. Stamler,et al. Identification of the enzymatic mechanism of nitroglycerin bioactivation , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[54] A. Semplicini,et al. Reduced content of alpha subunit of Gq protein content in monocytes of Bartter and Gitelman syndromes: relationship with vascular hyporeactivity. , 2002, Kidney international.
[55] L. P. Van den Heuvel,et al. Abnormalities of Gq-mediated cell signaling in Bartter and Gitelman syndromes. , 2001, Kidney international.
[56] R. Lifton,et al. Mutations in the Na-Cl Cotransporter Reduce Blood Pressure in Humans , 2001, Hypertension.
[57] S. Tenreiro,et al. Resistance and Adaptation to Quinidine in Saccharomyces cerevisiae: Role of QDR1 (YIL120w), Encoding a Plasma Membrane Transporter of the Major Facilitator Superfamily Required for Multidrug Resistance , 2001, Antimicrobial Agents and Chemotherapy.
[58] G. Lip,et al. ABC of hypertension: The pathophysiology of hypertension. , 2001, BMJ.
[59] J D Erickson,et al. Racial and temporal variations in the prevalence of heart defects. , 2001, Pediatrics.
[60] J. Horowitz,et al. Nitroglycerin Tolerance in Human Vessels: Evidence for Impaired Nitroglycerin Bioconversion , 2000, Circulation.
[61] D M Roden,et al. Antiarrhythmic drugs: from mechanisms to clinical practice , 2000, Heart.
[62] A. Semplicini,et al. Control of Vascular Tone in the Syndromes of Bartter and Gitelman , 2000, Critical reviews in clinical laboratory sciences.
[63] P. A. Friedman,et al. Diuretic effects on calcium metabolism. , 1999, Seminars in nephrology.
[64] G. Desir,et al. Defective processing and expression of thiazide-sensitive Na-Cl cotransporter as a cause of Gitelman's syndrome. , 1999, American journal of physiology. Renal physiology.
[65] A. Hughes,et al. Inhibition of carbonic anhydrase accounts for the direct vascular effects of hydrochlorothiazide. , 1999, Hypertension.
[66] G. Desir,et al. Defective processing and expression of thiazide-sensitive Na-Cl cotransporter as a cause of Gitelman's syndrome. , 1999, The American journal of physiology.
[67] A. Hughes,et al. Thiazide-induced vasodilation in humans is mediated by potassium channel activation. , 1998, Hypertension.
[68] A. Quyyumi,et al. Aspirin improves endothelial dysfunction in atherosclerosis. , 1998, Circulation.
[69] B. Lerman,et al. Adenosine and Cardiac Arrhythmias , 1998 .
[70] P. Ridker,et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. , 1997, The New England journal of medicine.
[71] M. Hartog,et al. Aspirin protects low density lipoprotein from oxidative modification. , 1997, Heart.
[72] Bang-Hun Lee. Treatment of Hypertension: Drug Therapy , 1997 .
[73] T. Paul,et al. Adenosine: An Effective and Safe Antiarrhythmic Drug in Pediatrics , 1997, Pediatric Cardiology.
[74] A. D'Angelo,et al. Increased urinary NO2-/NO3- and cyclic guanosine monophosphate levels in patients with Bartter's syndrome: relationship to vascular reactivity. , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[75] R. Lifton,et al. Gitelman's variant of Barter's syndrome, inherited hypokalaemic alkalosis, is caused by mutations in the thiazide-sensitive Na–Cl cotransporter , 1996, Nature Genetics.
[76] R Reilly,et al. Expression of the thiazide-sensitive Na-Cl cotransporter in rat and human kidney. , 1995, The American journal of physiology.
[77] H. Velázquez,et al. Expression of the thiazide-sensitive Na-Cl cotransporter by rabbit distal convoluted tubule cells. , 1995, The Journal of clinical investigation.
[78] R. Ferner,et al. Poisoning with anti-hypertensive drugs: angiotensin converting enzyme inhibitors. , 1995, Journal of human hypertension.
[79] P. Pickkers,et al. Relaxation and decrease in [Ca2+]i by hydrochlorothiazide in guinea‐pig isolated mesenteric arteries , 1995, British journal of pharmacology.
[80] W. S. Lee,et al. Molecular cloning, primary structure, and characterization of two members of the mammalian electroneutral sodium-(potassium)-chloride cotransporter family expressed in kidney. , 1994, The Journal of biological chemistry.
[81] J. Reid,et al. Blood pressure response to the first dose of angiotensin-converting enzyme inhibitors in congestive heart failure. , 1993, The American journal of cardiology.
[82] Y. Friedlander,et al. Diuretic-induced severe hyponatremia. Review and analysis of 129 reported patients. , 1993, Chest.
[83] A. Camm,et al. Adenosine and cardiac arrhythmias. , 1992, BMJ.
[84] V. Fuster,et al. The pathogenesis of coronary artery disease and the acute coronary syndromes (2). , 1992, The New England journal of medicine.
[85] R. N. Brogden,et al. Atenolol , 1991, Drugs.
[86] D. Ellison. The physiologic basis of diuretic synergism: its role in treating diuretic resistance. , 1991, Annals of internal medicine.
[87] K. Seibert,et al. Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice. , 1990, The Journal of clinical investigation.
[88] U. Borchard,et al. Classification and action of antiarrhythmic drugs. , 1989, European heart journal.
[89] C. Isles,et al. Profound hypotension after atenolol in severe hypertension. , 1989, BMJ.
[90] F. S. Wright,et al. Adaptation of the distal convoluted tubule of the rat. Structural and functional effects of dietary salt intake and chronic diuretic infusion. , 1989, The Journal of clinical investigation.
[91] N. Arber. Delirium induced by atenolol. , 1988, BMJ.
[92] P. Friedman. Biochemistry and pharmacology of diuretics. , 1988, Seminars in nephrology.
[93] V. Nerme,et al. The beta 1- and beta 2-adrenoceptor affinity of atenolol and metoprolol. A receptor-binding study performed with different radioligands in tissues from the rat, the guinea pig and man. , 1988, Biochemical pharmacology.
[94] J. M. Optiz,et al. Update on counseling the family with a first-degree relative with a congenital heart defect. , 1988, American journal of medical genetics.
[95] F. S. Wright,et al. Thiazide-sensitive sodium chloride cotransport in early distal tubule. , 1987, The American journal of physiology.
[96] S. Rahimtoola,et al. Changes in blood rheology in patients with stable angina pectoris as a result of coronary artery disease. , 1987, Circulation.
[97] L. Belardinelli,et al. Effect of Adenosine on Atrioventricular Conduction. I: Site and Characterization of Adenosine Action in the Guinea Pig Atrioventricular Node , 1986, Circulation research.
[98] F. S. Wright,et al. Effects of diuretic drugs on Na, Cl, and K transport by rat renal distal tubule. , 1986, The American journal of physiology.
[99] J. Vohra. Verapamil in cardiac arrhythmias: an overview. , 1982, Clinical and experimental pharmacology & physiology. Supplement.
[100] A. Yacobi,et al. Nitroglycerin pharmacokinetics after intravenous infusion in normal subjects. , 1981, Journal of pharmaceutical sciences.
[101] Bridget Wilcken,et al. Pathogenesis of coronary artery disease , 1969 .
[102] R. Jennings,et al. Structural Changes in Myocardium During Acute Ischemia , 1974, Circulation research.
[103] J. Vane,et al. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. , 1971, Nature: New biology.
[104] L. Resnekov. Cardiac Arrhythmias , 1964, Postgraduate medical journal.